AKBA News and Press, Akebia Therapeutics Inc. From 02/13/26

2026-02-13 16:57:51 ET Akebia Therapeutics, Inc. (AKBA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 February 12, 2026 9:30 AM EST... Read the full article on Seeking Alpha For further details see: Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securi...

CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside ...

2026-01-13 13:21:42 ET Thesis: Vafseo post sell-off As you know, Akebia Therapeutics, Inc. ( AKBA ) makes money mainly via the commercialisation of Vafseo. It's an oral therapy approved for the treatment of anaemia due to chronic kidney disease (CKD) in adults receiving dialysis...

2026-01-12 10:46:10 ET More on Akebia Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript Akebia Therapeutics: Dialysis-Only Path Puts VOCAL/Protocol Wins At The Core Akebia signals 7x increase in patient access for Vafseo entering 2026 amid operational...

 Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental glomerulosclerosis (FSGS) AKB-097 Phase 2 rare kidney disease basket trial scheduled to ...

CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the first patient has been dosed in a Phase 2 clinical trial of p...

Q32 Bio Sells Complement Inhibitor ADX-097 PR Newswire -- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the sec...

Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stimulator, initiated in focal segm...

CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate ...

2025-11-10 11:02:38 ET More on Akebia Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript Akebia Therapeutics: Dialysis-Only Path Puts VOCAL/Protocol Wins At The Core Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Confer...